Texas to create response team to combat New World screwworms
AUSTIN (KXAN) — Texas Gov. Greg Abbott (R) on Wednesday directed two state agencies to assemble a response team to combat the New World screwworm, which poses a serious threat to Texas livestock and wildlife.
According to the Centers for Disease Control and Prevention, New World screwworms are a species of fly larvae that infest and feed off the flesh of warm-blooded animals.
RELATED | Texas officials warn of infectious, parasitic screwworms found in Mexico
In a news release, Abbott said, 'The mission for the Response Team is clear: to lead Texas' prevention and response efforts and ensure that Texas remains informed, prepared, and aligned to prevent the re-emergence of this destructive parasite.'
The Texas Parks and Wildlife Department (TPWD) and the Texas Animal Health Commission (TAHC) are responsible for establishing the Texas New World Screwworm Response Team.
'As a border state, Texas represents the first line of defense against the potential re-entry of this harmful pest into the United States,' Abbott wrote in a letter to TPWD and TAHC. 'Texas played a critical role in eradicating this pest from the United States in the 1960s and will do so again if the need arises.'
RELATED | US plans to open a fly factory in Texas as part of its fight against a flesh-eating parasite
Agriculture Secretary Brooke Rollins recently announced a multi-national program to stop the spread of screwworms.
The U.S. planned to invest $8.5 million in a dispersal site from Moore Air Base and $20 million in a facility in Mexico that produces sterilized screwworms. The insects will then be released by planes over Mexico to stop them from coming to the U.S.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
2 days ago
- Time Magazine
TIME100 Most Influential Companies 2025: Abbott
Medical device and health care giant Abbott received FDA clearance in 2024 for two over-the-counter continuous glucose monitors, including one of the first over-the-counter devices available to U.S. consumers who don't have diabetes or hypoglycemia. The company is capitalizing on growing public awareness of the relationship between blood sugar and health, as well as the popularity of health-related wearables, and now lets any U.S. resident understand how diet, exercise, and lifestyle impact their metabolic health without a prescription. 'Abbott innovation is providing two things you need most when it comes to your health: knowledge and power,' says Abbott chairman and CEO Robert Ford. 'With financial and staffing constraints in health care, our goal is to make health information and treatment more accessible, whenever and wherever it is needed.'The FDA also gave Abbott the green light in September 2024 to launch a clinical trial evaluating the effectiveness of the company's deep brain stimulation (DBS) system in patients with treatment-resistant depression (TRD)—a form of major depression that has not responded to two or more different types of traditional therapies including medications.
Yahoo
2 days ago
- Yahoo
Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever
Annual healthcare expenditures in the United States alone approach $5 trillion. Healthcare industry leaders have proven remarkably consistent as dividend growers. Abbott, J&J, Medtronic, Cardinal Health, and West Pharmaceutical are all worth a closer look. 10 stocks we like better than Johnson & Johnson › The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's passive income stream and never have to work another day in their life. The trick is finding the right stocks. There aren't many businesses that can deliver decade after decade. That said, the healthcare industry is a great place to look for such companies. Healthcare spending is in the trillions of dollars annually in the United States alone, and the desire for better care and more of it is only expanding as the world's population grows and the median age rises. Here are five proven healthcare winners that can deliver decades of passive income. Nothing is truly forever, but these stocks are about as close as you can get. It's hard not to start with Johnson & Johnson (NYSE: JNJ). The stock is a Dividend King with a streak of 62 consecutive annual dividend increases. It's among the world's leading developers of pharmaceuticals, medical devices, and products. It's an industry titan with a fortress-like balance sheet that enables it to balance dividend increases with strategic acquisitions and product development, driving steady growth. At its current share price, the stock offers a solid 3.5% dividend yield, and its payout ratio is a cozy 49% of 2025 earnings estimates. Johnson & Johnson is growing earnings at a mid-single-digit percentage pace annually, so it won't make you rich quickly. However, reinvest those dividends, and your Johnson & Johnson holding could eventually become a cash cow for your portfolio. The Dividend Kings club is a small group, but it includes another long-standing industry giant: Abbott Laboratories (NYSE: ABT). That company has raised its dividends annually for 53 consecutive years. After spinning off its pharmaceutical business as AbbVie over a decade ago, Abbott has centered its business around medical devices for cardiovascular and diabetes patients, as well as diagnostics and consumer nutrition products. Abbott should remain a dependable dividend payer for years to come. At the current share price, its yield is just under 1.8%, but investors can expect some notable dividend increases in the near future. Analysts expect Abbott to grow its earnings by 10% annually over the next three to five years, and the payout ratio is only 45% of 2025 earnings estimates. Some of healthcare's most essential players operate behind the scenes. Cardinal Health (NYSE: CAH), for example, is a global distributor of pharmaceuticals and healthcare products to hospitals, care providers, and patients. The company has also built a strong reputation as a dividend stock, with 30 consecutive years of payout hikes. The stock yields 1.2% at its current share price, but there is considerable room for management to increase the dividend. Its payout ratio is barely a quarter of this year's estimated earnings, and analysts project nearly 11% annualized earnings growth over the next three to five years. Cardinal Health is an excellent stock for investors who have time to let those dividend increases stack up for a couple of decades. Another under-the-radar name, West Pharmaceutical Services (NYSE: WST), designs and sells delivery systems for injectable medicines. Its products include stoppers and plungers in injection devices, wearable injectors, and injection pens. The company's business has gradually shifted from standardized offerings to more advanced, proprietary products that carry higher profit margins. That bodes well for the company's dividend, which it has already raised for 32 consecutive years. Additionally, the dividend payout ratio remains at only 13% of 2025 earnings estimates, and the business is poised to grow at a mid-to-high single-digit percentage pace. So, while its current yield is just 0.4%, investors can expect their payouts to rise steadily for many years to come. Closing out this list is medical device and equipment giant Medtronic (NYSE: MDT). It specializes in products and equipment used by patients and healthcare professionals for a wide range of conditions and care categories. The company is on course to become a Dividend King, with management's dividend-hiking streak currently at 47 years. The stock also offers a solid yield of 3.2% at the current share price. Medtronic's diverse product portfolio and history of continuous innovation have driven its consistent growth for generations. Today, the company has nearly 200 clinical trials underway and over 43,000 active patent matters. The dividend remains safe with a comfortable 50% payout ratio, while analysts expect annualized earnings growth of 6% to 7% moving forward. Investors who buy and hold Medtronic can expect more of what the company has already delivered for decades now. Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!* Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Chicago Tribune
3 days ago
- Chicago Tribune
Nestle says it will remove artificial dyes from US foods by 2026
Nestle said Wednesday it will eliminate artificial colors from its U.S. food and beverages by the middle of 2026. It's the latest big food company making that pledge. Last week, Kraft Heinz and General Mills said they would remove artificial dyes from their U.S. products by 2027. General Mills also said it plans to remove artificial dyes from its U.S. cereals and from all foods served in K-12 schools by the middle of 2026. The move has broad support. About two-thirds of Americans favor restricting or reformulating processed foods to remove ingredients like added sugar or dyes, according to an AP-NORC poll. Both California and West Virginia have recently banned artificial dyes in foods served in schools. On Sunday, Republican Gov. Greg Abbott of Texas signed a bill requiring foods made with artificial dyes or additives to contain a new safety label starting in 2027. The label would say they contain ingredients 'not recommended for human consumption' in Australia, Canada, the European Union or the U.K. The federal government is also stepping up its scrutiny of artificial colors. In January, days before President Donald Trump took office, the U.S. regulators banned the dye called Red 3 from the nation's food supply, nearly 35 years after it was barred from cosmetics because of potential cancer risk. In April, Trump's Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said the agency would take steps to eliminate synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry. Nestle has pledged to remove artificial dyes before. Early in 2015, the company said it would remove artificial flavors and colors from its products by the end of that year. But the promise didn't hold. Nestle said Wednesday it's been removing synthetic dyes from its products over the last decade, and 90% of its U.S. portfolio doesn't contain them. Among those that do is Nesquik Banana Strawberry milk, which is made with Red 3. Nestle said Wednesday it wants to evolve with its U.S. customers' changing nutritional needs and preferences. 'Serving and delighting people is at the heart of everything we do and every decision that we make,' Nestle's U.S. CEO Marty Thompson said in a statement.
